HRT, Mood, and a Study That Actually Surprised Me
Quick Summary
Three stories today: a real-world study finding that systemic hormone therapy may improve mood in midlife women regardless of their mental health history, new cardiovascular data linking HRT use to meaningfully lower mortality risk, and California's push to bring menopause care into its prison system. All three touch what happens when women finally get access to care — and what it costs them when they don't.
HRT, Mood, and a Study That Actually Surprised Me
Key Takeaways
- ✦A new retrospective study published in the NAMS journal found that systemic hormone therapy was associated with improved mood symptoms in midlife women, including those without a prior mental health diagnosis or antidepressant use.
- ✦The mood benefit appeared strongest in women who started with the most severe symptoms — not a mild nudge at the margins, but a meaningful shift for the women who needed it most.
- ✦Data from the Multi-Ethnic Study of Atherosclerosis found that women who used hormone therapy had significantly lower rates of all-cause death compared to women who never used it or had stopped — a finding that held up after adjustment for factors like coronary artery calcium.
- ✦California has begun piloting menopause care programs inside its state prisons — making it one of the first states to formally address menopause as a health need for incarcerated women.
- ✦The cardiovascular mortality finding did not reach statistical significance for heart disease specifically, which is worth knowing — but the all-cause mortality result was significant, and that distinction matters.
Sources & References
Episode Script
Thanks Toni. We've got a good one today.
Three items on the table. Two new studies out of the NAMS journal — one on hormone therapy and mood, one on hormone therapy and heart health and mortality — and a piece from the LA Times about California doing something genuinely interesting inside its prison system. Let's get into it.
The first study is called "Impact of hormone therapy on mood in a real-world clinical setting," and it's retrospective, meaning researchers went back through existing patient records rather than running a controlled experiment. That's an important caveat to carry with you, and I'll come back to it.
The finding: women who used systemic hormone therapy — that's HRT taken as a pill or patch that works throughout the body, not just a local vaginal cream — showed improvement in mood symptoms over the course of midlife. And the improvement held up regardless of whether the woman had a prior mental health diagnosis, whether she was already on antidepressants, and regardless of where she was in the menopause transition.
That last part is the piece I'd flag. Because one of the arguments you hear against treating mood symptoms with HRT is basically: "well, you might just be depressed, and depression is separate from menopause, so we should treat the depression directly." What this study pushes back on is the assumption that those two things are neatly separable. For a lot of women, they're not.
The study also found that the women who showed the biggest mood improvement were the ones who came in with the most severe symptoms to start. Not a small effect at the edges — a real shift for the women who were struggling the most.
Now. Retrospective observational study. That means we cannot say hormone therapy caused the mood improvement. Women who sought out HRT may have had other things going for them — access to good care, generally engaged with their health, other lifestyle factors. The study can't fully account for that. It's the kind of limitation that matters, and it's the kind the researchers acknowledged.
What I'd say about this one: it adds real-world weight to a case that's been building in the clinical literature for a while. The evidence that estrogen plays a role in mood regulation during perimenopause and menopause is not new — the biology behind it is fairly well established. What studies like this one do is show that the effect actually shows up in actual patients, not just in tightly controlled trial conditions. That matters for how doctors think about it in the exam room.
If you've been told your mood issues and your menopause are two separate problems requiring two separate tracks of treatment — this study is worth bringing up with your provider. Not as proof, but as a conversation starter. The evidence is moving.
The California prisons piece ran as a contributor piece in the LA Times, and I want to spend a minute on it because it's easy to read past and I don't think you should.
California has started piloting menopause care programs inside its state prisons. The piece frames it as California leading the way — and maybe it is, because as far as I can find, no other state has made this a formal, structured effort.
The women inside these facilities are going through the same hormonal shifts as everyone else. Hot flashes, night sweats, sleep disruption, mood changes, joint pain, brain fog — all of it. And historically, they've been almost entirely invisible in the menopause conversation. The menopause wellness market is built around a very specific image of who has menopause: someone with disposable income, access to a functional ob-gyn, and time to optimize. Incarcerated women are about as far from that image as you can get, and they've largely been treated accordingly.
What the California program is trying to do is bring basic menopause education and care access into a setting where it has never existed. Symptom recognition, treatment options, provider training. The fundamentals.
My take on this: the bar here is genuinely low, and California clearing it is worth acknowledging without overstating it. Getting your doctor to recognize that you're in perimenopause and not having a psychiatric episode — that's not a high bar. But for women inside these facilities, even that basic level of recognition has often been missing. So yes, credit where it's due. And also: the fact that this is news, that it's framed as leading the way, tells you something about how far behind the baseline of menopause care still is for women who aren't in a position to advocate loudly for themselves.
The broader pattern that bothers me: menopause care tends to reach women in proportion to their social and economic power. Women with money, education, good insurance, and assertive communication styles get care. Women without those things — whether they're uninsured, in underserved communities, or in a prison — get overlooked. California taking a step toward fixing one slice of that is genuinely good. It should also not be exceptional.
The third item is a study from the Multi-Ethnic Study of Atherosclerosis — a large, long-running cardiovascular research project — looking at hormone therapy use and risk of death. I want to be precise about what it found, because the headline version and the nuanced version are pretty different.
The headline version: women who used hormone therapy had significantly lower all-cause mortality compared to women who never used it or had stopped. That's a striking finding. Statistically significant, held up after the researchers adjusted for a number of factors including something called coronary artery calcium — which is basically a measure of plaque buildup in the arteries around your heart. It's used as a marker of cardiovascular risk.
The nuanced version: the lower rates of heart disease deaths and coronary heart disease specifically — those trended lower for HRT users, but did not reach statistical significance once the researchers accounted for other variables. That means we can't confidently say from this study that HRT protects specifically against dying from heart disease. What we can say is that overall, the women who used HRT in this dataset were significantly less likely to die during the follow-up period, from any cause.
That distinction is worth understanding. "All-cause mortality" means death from anything — cancer, accidents, infections, cardiovascular events, everything pooled together. A significant result there is meaningful. But it's a broader, blunter measure than saying "HRT reduces your risk of a heart attack specifically." The specific cardiovascular claims are still more complicated.
The timing-of-HRT question — whether starting early in menopause matters more than starting later — is not something this study answers cleanly. It's a real question in the literature, and other research, including data your doctor might look at on a tool like OpenEvidence, suggests that timing does matter for cardiovascular outcomes. This study adds to the picture but doesn't settle that.
What I take from this one: the mortality signal is real and significant, and in a study that followed a racially and ethnically diverse group of women — which is not a given in this research space, and is one of the things that makes the Multi-Ethnic Study of Atherosclerosis worth paying attention to — that matters. The cardiovascular-specific results are more tentative. Both things are true, and a study that gets reported as "HRT cuts heart risk" when the actual finding is more specific and more conditional is a study being oversold. This one isn't nothing. It's also not the final word.
Sources curated automatically by the Hot Flasher pipeline.
Hot Flasher provides informational content only and does not constitute medical advice. Always consult a qualified healthcare provider for medical concerns.